Savara (SVRA) Issues Quarterly Earnings Results

Savara (NASDAQ:SVRA) announced its quarterly earnings results on Thursday. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.05, Morningstar.com reports.

Shares of NASDAQ SVRA traded up $0.49 during midday trading on Friday, reaching $11.21. 146,741 shares of the company traded hands, compared to its average volume of 339,619. The stock has a market cap of $384.10 million, a PE ratio of -8.69 and a beta of 1.07. Savara has a 12 month low of $6.21 and a 12 month high of $14.06. The company has a debt-to-equity ratio of 0.23, a quick ratio of 15.63 and a current ratio of 15.63.

In other news, COO Jaakko Taneli Jouhikainen sold 7,815 shares of the firm’s stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $9.00, for a total value of $70,335.00. Following the completion of the sale, the chief operating officer now directly owns 184,754 shares in the company, valued at $1,662,786. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO David L. Lowrance sold 7,500 shares of the firm’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $9.02, for a total value of $67,650.00. Following the completion of the sale, the chief financial officer now owns 2,446 shares of the company’s stock, valued at $22,062.92. The disclosure for this sale can be found here. Over the last three months, insiders have sold 50,261 shares of company stock valued at $466,674. Company insiders own 6.10% of the company’s stock.

Large investors have recently made changes to their positions in the company. Simplex Trading LLC increased its stake in shares of Savara by 246.1% in the fourth quarter. Simplex Trading LLC now owns 4,997 shares of the company’s stock valued at $37,000 after buying an additional 3,553 shares in the last quarter. Virtu Financial LLC acquired a new stake in Savara in the fourth quarter worth about $82,000. Jane Street Group LLC acquired a new stake in Savara in the fourth quarter worth about $93,000. DekaBank Deutsche Girozentrale increased its position in Savara by 19.4% in the first quarter. DekaBank Deutsche Girozentrale now owns 12,300 shares of the company’s stock worth $141,000 after purchasing an additional 2,000 shares during the period. Finally, D. E. Shaw & Co. Inc. acquired a new stake in Savara in the fourth quarter worth about $111,000. Institutional investors own 47.87% of the company’s stock.

Several equities research analysts have recently weighed in on the company. Zacks Investment Research raised Savara from a “sell” rating to a “hold” rating in a research report on Saturday, March 2nd. BidaskClub raised Savara from a “sell” rating to a “hold” rating in a report on Tuesday, March 12th. ValuEngine raised Savara from a “sell” rating to a “hold” rating in a report on Monday, April 1st. Finally, LADENBURG THALM/SH SH reissued a “buy” rating and set a $21.00 price objective on shares of Savara in a report on Monday, April 1st. Three analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $21.17.

COPYRIGHT VIOLATION WARNING: “Savara (SVRA) Issues Quarterly Earnings Results” was first posted by Transcript Daily and is the property of of Transcript Daily. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://transcriptdaily.com/2019/05/11/savara-svra-issues-quarterly-earnings-results.html.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

See Also: Understanding Relative Strength Index

Earnings History for Savara (NASDAQ:SVRA)

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.